Sever Pharma Solutions Secures DEA License for Controlled Substances Handling in Putnam, CT

Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs is pleased to announce the successful attainment of the Drug Enforcement Administration (DEA) license for its site in Putnam, CT. This license, effective as of December 15th, 2023, authorizes Sever Pharma Solutions to handle controlled substances, specifically those classified under Schedule 3-5.

DEA License for Controlled Substances Handling
The DEA license grants Sever Pharma Solutions the authority to possess, manufacture, distribute, and conduct research and development activities involving controlled substances. This regulatory approval is a testament to Sever Pharma Solutions’ compliance with stringent DEA regulations and its dedication to fostering a secure and controlled environment for handling pharmaceutical materials.
Kenneth Stokholm, CEO of Sever Pharma Solutions, commented on the achievement, saying:
“We are thrilled to announce the successful obtainment of the DEA license for controlled substances handling at our Putnam, CT, facility. This achievement reflects our unwavering commitment to upholding the highest standards in pharmaceutical operations. The license not only enhances our capabilities but also strengthens our position as a trusted partner in the pharmaceutical industry.”

Upcoming Milestone: High Potent Facility
As part of its continued growth strategy, Sever Pharma Solutions is on track to completing the construction of a high potent facility at the same site in Putnam by the end of Q1 2024. This facility will further enhance Sever Pharma Solutions’ capabilities in handling high potent drug products, providing state-of-the-art infrastructure for the development and manufacturing of cutting-edge pharmaceutical solutions.

Kenneth Stokholm, CEO of Sever Pharma Solutions